immunoglobulin G, human 10 % in 25 ML Injection [PSN] · 25 ML immunoglobulin G, human 100 MG/ML Injection [SCD] · immunoglobulin G, human 10 % per 25 ML Injection [SY] · immunoglobulin G, human 2.5 GM per 25 ML Injection [SY]
4
37
These highlights do not include all the information needed to use GAMUNEX ® -C safely and effectively. See full prescribing information for GAMUNEX-C. GAMUNEX ® -C, [Immune Globulin Injection (Human), 10% Caprylate/Chromatography Purified] Initial U.S. Approval: 2003
immunoglobulin G, human 10 % in 25 ML Injection [PSN] · 25 ML immunoglobulin G, human 100 MG/ML Injection [SCD] · immunoglobulin G, human 10 % per 25 ML Injection [SY] · immunoglobulin G, human 2.5 GM per 25 ML Injection [SY]
4
34
These highlights do not include all the information needed to use GAMMAKED™ safely and effectively. See full prescribing information for GAMMAKED. GAMMAKED™, [Immune Globulin Injection (Human), 10% Caprylate/ Chromatography Purified] Initial U.S. Approval: 2003
immunoglobulin G, human 10 % in 25 ML Injection [PSN] · 25 ML immunoglobulin G, human 100 MG/ML Injection [SCD] · immunoglobulin G, human 10 % per 25 ML Injection [SY] · immunoglobulin G, human 2.5 GM per 25 ML Injection [SY]
4
22
These highlights do not include all the information needed to use HYQVIA ® safely and effectively. See full prescribing information for HYQVIA. HYQVIA ® [Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase] Solution, for subcutaneous administration Initial U.S. Approval: 2014
immunoglobulin G, human 10 % in 25 ML Injection [PSN] · 25 ML immunoglobulin G, human 100 MG/ML Injection [SCD] · immunoglobulin G, human 10 % per 25 ML Injection [SY] · immunoglobulin G, human 2.5 GM per 25 ML Injection [SY]
4
22
These highlights do not include all the information needed to use GAMMAGARD LIQUID ® safely and effectively. See full prescribing information for GAMMAGARD LIQUID. GAMMAGARD LIQUID ® , Immune Globulin Infusion (Human), 10% Solution, for intravenous and subcutaneous administration Initial U.S. Approval: 2005